Newsroom

Keep up with our latest news.

July 2022

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

All
Press Releases

September 05, 2023

Press Releases

Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference Read More

August 16, 2023

Press Releases

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021 Read More

August 03, 2023

Press Releases

Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements Read More

July 13, 2023

Press Releases

Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer Read More

June 09, 2023

Press Releases

Elevation Oncology Announces Pricing of $50 Million Public Offering Read More

June 08, 2023

Press Releases

Elevation Oncology Announces Launch of Proposed Public Offering Read More

Pages: 12345678

Investor Resources

Follow our journey with our latest Investor Resources

Press Releases

Read the latest News Releases for Investors

Events

Browse the calendar to view Investor related events and announcements. Webcasts and presentations that have been archived are available by viewing historical event details.

SEC Filings

Review all of Elevation's SEC filings

Track our progress

Check back often for our latest insights, or sign up for our mailing list to receive the have the latest news and publications from Elevation Oncology delivered to your inbox.